Published in Nat Rev Neurol on October 13, 2009
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology (2014) 1.43
Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol (2011) 1.15
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler (2012) 1.01
Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol (2015) 0.94
Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol (2011) 0.93
Multiple sclerosis in children. Iran J Child Neurol (2013) 0.88
Acquired demyelinating disorders of central nervous system: A pediatric cohort. Ann Indian Acad Neurol (2015) 0.85
Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis (2013) 0.83
Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int (2014) 0.81
The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data. Hum Vaccin Immunother (2015) 0.80
Management of multiple sclerosis in adolescents - current treatment options and related adherence issues. Adolesc Health Med Ther (2010) 0.77
Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology (2017) 0.75
Axonal Damage in Pediatric Multiple Sclerosis. Pediatr Neurol Briefs (2015) 0.75
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. Curr Neurol Neurosci Rep (2016) 0.75
Pediatric multiple sclerosis-a challenging demyelinating disease: case report and brief review of the literature. Case Rep Pediatr (2012) 0.75
Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients. Neuroimage Clin (2014) 0.75
Genetic predictors of relapse rate in pediatric MS. Mult Scler (2016) 0.75
Paediatric clinically isolated syndromes: report of seven cases, differential diagnosis and literature review. Childs Nerv Syst (2015) 0.75
Hospital admission rates for pediatric multiple sclerosis in the United States using the Pediatric Health Information System (PHIS). Mult Scler Relat Disord (2016) 0.75
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology (2007) 4.23
Cognitive impairment in multiple sclerosis. Lancet Neurol (2008) 3.77
Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology (2001) 3.01
Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain (2000) 2.96
Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology (2002) 2.90
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology (2008) 2.87
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Role of MRI in the differentiation of ADEM from MS in children. Neurology (2008) 1.94
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol (2007) 1.73
Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology (2008) 1.70
Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology (2005) 1.65
Optical coherence tomography in multiple sclerosis. Lancet Neurol (2006) 1.65
Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler (1997) 1.65
Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol (2001) 1.64
Incidence of acquired demyelination of the CNS in Canadian children. Neurology (2009) 1.63
Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology (2009) 1.62
Pediatric multiple sclerosis: detection of clinically silent lesions by multimodal evoked potentials. J Pediatr (2006) 1.61
Early relapse risk after a first CNS inflammatory demyelination episode: examining international consensus definitions. Dev Med Child Neurol (2007) 1.52
Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J (2004) 1.52
Multiple sclerosis in childhood: report of 15 cases. Brain Dev (1991) 1.51
Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol (2009) 1.50
Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology (2008) 1.50
Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol (2006) 1.49
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr (1987) 1.48
Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol (1995) 1.46
High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology (2006) 1.44
Early onset multiple sclerosis: a longitudinal study. Neurology (2002) 1.43
Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler (2009) 1.41
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain (2004) 1.31
Cognitive functioning in children and adolescents with multiple sclerosis. Neurology (2005) 1.28
Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology (2002) 1.23
Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand (1992) 1.19
The cognitive burden of multiple sclerosis in children. Neurology (2005) 1.13
Longitudinal neuropsychological assessment in pediatric multiple sclerosis. Dev Neuropsychol (2007) 1.06
Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol (2008) 1.05
Prospective study of multiple sclerosis with early onset. Mult Scler (2002) 1.05
Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr (2007) 1.04
Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology (2006) 1.03
Multiple sclerosis vs acute disseminated encephalomyelitis in childhood. Pediatr Neurol (2003) 1.03
Definite and suspected multiple sclerosis in children: long-term follow-up and magnetic resonance imaging findings. J Child Neurol (2001) 1.02
Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol (2008) 1.01
Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain (2007) 1.01
Multiple sclerosis in children; a clinical study of 40 cases with onset in childhood. Pediatrics (1958) 1.00
MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort. Neurology (2004) 0.98
The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg (2002) 0.97
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology (2006) 0.97
Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. Mult Scler (2009) 0.96
CSF characteristics in early-onset multiple sclerosis. Neurology (2004) 0.96
Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. Mult Scler (2008) 0.95
Natalizumab use in pediatric multiple sclerosis. Arch Neurol (2008) 0.94
Pediatric-onset multiple sclerosis in African-American black and European-origin white patients. Pediatr Neurol (2009) 0.93
Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. Brain Dev (2003) 0.93
Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology (2006) 0.91
Pediatric multiple sclerosis. Curr Treat Options Neurol (2009) 0.90
A long perspective on childhood multiple sclerosis. Dev Med Child Neurol (1995) 0.90
Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci (2007) 0.90
Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr (2001) 0.88
Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol (2007) 0.88
Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics (2003) 0.88
Switching algorithms: from one immunomodulatory agent to another. J Neurol (2008) 0.86
Childhood-onset multiple sclerosis: report of 82 patients from Isfahan, Iran. Arch Iran Med (2007) 0.85
Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol (2008) 0.85
Identifying and treating patients with suboptimal responses. Neurology (2004) 0.85
Clinically observed chickenpox and the risk of childhood-onset multiple sclerosis. Am J Epidemiol (2009) 0.85
Clinical characteristics and long term prognosis in early onset multiple sclerosis. J Neurol (2006) 0.84
Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan. Brain Dev (2005) 0.84
Juvenile multiple sclerosis: clinical features and prognostic characteristics. J Pediatr (1998) 0.84
Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence. J Neurol (2008) 0.82
Myelin basic protein and myelin oligodendrocyte glycoprotein T-cell repertoire in childhood and juvenile multiple sclerosis. Mult Scler (2006) 0.82
Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci (2002) 0.81
Multiple sclerosis in childhood: report of 16 cases. Eur Neurol (1996) 0.81
Multiple sclerosis in children: report of clinical and paraclinical features of 19 cases. Neuropediatrics (1988) 0.81
[The use of beta-interferon-1b in children and adolescents with multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova (2006) 0.79
Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol (2005) 0.78
Pediatric multiple sclerosis report of 14 cases. Brain Dev (1995) 0.77
Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain (2007) 0.77
Very early onset multiple sclerosis. Dev Med Child Neurol (1995) 0.77
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Acute disseminated encephalomyelitis. Neurology (2007) 2.84
CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol (2003) 2.79
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler (2013) 2.20
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Body size and risk of MS in two cohorts of US women. Neurology (2009) 1.89
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol (2011) 1.85
Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology (2009) 1.80
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest (2003) 1.76
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2013) 1.51
Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol (2009) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol (2014) 1.50
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology (2013) 1.46
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy. Muscle Nerve (2011) 1.42
The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler (2014) 1.36
Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther (2005) 1.36
Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler (2006) 1.34
Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci (2006) 1.31
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol (2012) 1.18
Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med (2015) 1.18
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol (2012) 1.18
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol (2013) 1.15
Smoking and disease progression in multiple sclerosis. Arch Neurol (2009) 1.13
CD4+ T cells regulate surgical and postinfectious adhesion formation. J Exp Med (2002) 1.11
Acute flaccid paralysis with anterior myelitis - California, June 2012-June 2014. MMWR Morb Mortal Wkly Rep (2014) 1.10
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet (2013) 1.09
Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol (2010) 1.09
Modeling disease severity in multiple sclerosis using electronic health records. PLoS One (2013) 1.06
Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol (2010) 1.04
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol (2006) 1.04
Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol (2008) 1.03
Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One (2011) 1.02
Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol (2009) 1.01
Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt (2011) 0.99
Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health (2012) 0.97
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport (2014) 0.95
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One (2013) 0.94
Pediatric multiple sclerosis. Neurol Clin (2011) 0.93
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol (2006) 0.93
MS and the B cell controversy. Biochim Biophys Acta (2010) 0.93
Sexual disparities in the incidence and course of MS. Clin Immunol (2013) 0.92
CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci (2010) 0.92
Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry (2011) 0.92
The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res (2012) 0.91
Effect of gender on late-onset multiple sclerosis. Mult Scler (2012) 0.90
Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int (2013) 0.90
International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology (2013) 0.89
Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol (2009) 0.88
Pathogenesis of pediatric multiple sclerosis. J Child Neurol (2012) 0.88
A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One (2010) 0.87
Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol (2014) 0.87
No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol (2013) 0.86
A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2008) 0.85
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci (2011) 0.85
Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother (2010) 0.85
Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler (2012) 0.85
Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis. Mult Scler (2011) 0.84
Does race matter for multiple sclerosis? Neurology (2010) 0.84
Pediatric multiple sclerosis. Ann Indian Acad Neurol (2009) 0.84
Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. J Neuroimmunol (2007) 0.84
Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler (2011) 0.84
Pediatric multiple sclerosis. NeuroRx (2006) 0.84
Health-related quality of life is reduced in pediatric multiple sclerosis. Pediatr Neurol (2010) 0.83
Pediatric multiple sclerosis. Curr Neurol Neurosci Rep (2008) 0.83